首页 工具
登录
购物车

搜索结果

Search Results for " mutant idh1 inhibitor "

20

抑制剂 & 化合物

1

天然产物

如果没找到您满意的产品或者您对产品有其他要求,可以联系我们专业顾问为您提供针对性的合理建议。     QQ咨询       网站留言咨询

提交您的定制咨询

点击图片重新获取验证码
Cat. No. Product Name Target Signaling Pathways
T16161 Mutant IDH1 inhibitor

Dehydrogenase; Isocitrate Dehydrogenase (IDH) Metabolism
Mutant IDH1 inhibitor 是一种突变型IDH1 R132H 的抑制剂,IC50<72 nM。
T2043 Mutant IDH1-IN-1

IDH1-IN-1

Dehydrogenase; Isocitrate Dehydrogenase (IDH) Metabolism
Mutant IDH1-IN-1IDH1突变体的选择性抑制剂,能够作用于突变体 IDH1 R132C/R132C (IC50:4 nM) ,IDH1 R132H/R132H (IC50:42 nM) ,IDH1 R132H/WT (IC50:80 nM) 和野生型 IDH1 (IC50:143 nM)。
T12128 Mutant IDH1-IN-2

Isocitrate Dehydrogenase (IDH) Metabolism
Mutant IDH1-IN-2是突变型异柠檬酸脱氢酶蛋白抑制剂, 在荧光生物化学检测中IC50为16.6 nM,LS-MS 生物化学检测中IC50为<22 nM,。
T15551 IDH889

Dehydrogenase Metabolism
IDH889 是可口服有效的,脑渗透性的,变构和突变特异性的异柠檬酸脱氢酶抑制剂,对 IDH1 R132* 突变型具有高效选择性。它高效抑制细胞内 2-HG 水平,IC50为 0.014 μM。
T15550 IDH-305

Dehydrogenase Metabolism
IDH-305 是突变选择性的、口服性的、脑渗透性的 IDH1抑制剂,靶向 IDH1 (R132) 突变。它对突变体 IDH1 亚型的选择性比野生型高 200 倍 (IC50= 27 nM (IDH1R132H), 28 nM (IDH1R132C), 6.14 µM (IDH1WT))。
TQ0042 BAY-1436032

Dehydrogenase; Isocitrate Dehydrogenase (IDH) Metabolism
BAY-1436032 是一种选择性泛突变异柠檬酸脱氢酶 1 新型口服抑制剂。
T16384 Olutasidenib

FT-2102

Dehydrogenase; Isocitrate Dehydrogenase (IDH) Metabolism
Olutasidenib (FT-2102) 是一种可透过血脑屏障的、具有口服活性的、突变型异柠檬酸脱氢酶(IDH)1的选择性有效抑制剂,对IDH1- R132H 和 IDH1- R132C 的IC50分别为 21.2 nM 和 114 nM,可用于急性髓性白血病或骨髓增生异常综合征的研究。
T11612 IDH1 Inhibitor 3

Others Others
IDH1 Inhibitor 3 is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor (IC50: 45 nM for IDH1R132H).
T12129 Mutant IDH1-IN-4

Others Others
Mutant IDH1-IN-4 is an mutant Isocitrate dehydrogenase 1 (IDH 1) inhibitor.
T62725 IDH1 Inhibitor 5

IDH1 Inhibitor 5 (compound 2) 是一种 IDH1(异柠檬酸脱氢酶 1)的抑制剂。IDH1 Inhibitor 5 能够抑制 MOG 细胞 (IC50: 64.4 nM) 以及表达外源突变 IDH1 R132H 蛋白的野生型 IDH1 胶质瘤细胞 (IC50: 34.9 nM)。
T70890 ML309

ML309 is a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. ML309 is capable of potent and selective inhibition of mutant IDH1 and effectively lowers cell-based production of 2-HG in a U87MG mutant glioblastoma cell line.
T11613 IDH1 Inhibitor 1

Others Others
IDH1 Inhibitor 1 is an orally bioavailable, brain-penetrant, and selective mutant IDH1 inhibitor (IC50s: 0.021 μM, 0.045 μM, and 2.52 μM for IDH1R132H, IDH1R132C, and IDH1WT).
T15442 GSK864

Others Others
GSK864 is an inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant. GSK864 inhibits IDH1 mutants R132C, R132H, and R132G (IC50: 8.8, 15.2, and 16.6 nM).
T63403 WT IDH1 Inhibitor 2

WT IDH1 Inhibitor 2 是一种野生型异柠檬酸脱氢酶1 (WT IDH1) 抑制剂 (IC50: 120 nM),是突变体R132H IDH1抑制剂,是 GSK321 的异构体,具有野生型交叉反应性。
T63778 Safusidenib

Safusidenib 是选择性的、口服具有活力的 IDH1 突变型抑制剂,对突变型 IDH1 具有显著抑制作用,但不能抑制野生型 IDH1,能够抑制软骨肉瘤中的肿瘤活性。Safusidenib 对IDH1R132H 和 IDH1R132C 具有活性,在没有预孵育的情况下,IC50 值分别为 15 和 130 nM。
T32009 GSK321

GSK 321,GSK-321

GSK321 is an effective and selective IDH1 mutation inhibitor, which can effectively inhibit the production of 2-HG in HT-1080 cells, and induce IDH1 mutant cells to differentiate into bone marrow at the level of leukemia blasts and more stem cells.
T38004 ML-309 (hydrochloride)

ML-309 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). It reversibly and selective inhibits IDH1R132H over wild-type IDH1 (IC50s = 96 and 36,500 nM, respectively). ML-309 reduces 2-hydroxyglutarate production in U87 MG glioblastoma cells (EC50 = 55 nM).
T63402 (S,R)-WT IDH1 Inhibitor 2

(S,R)-WT IDH1 Inhibitor 2 是选择性的、有效的突变型 IDH1抑制剂,能够抑制 R132G (IC50: 2.9 nM)、R132C (IC50: 3.8 nM)、R132H (IC50: 4.6 nM) 和 WT IDH1 (IC50: 46 nM),选择性比 IDH2 高出 100 倍。(S,R)-WT IDH1 Inhibitor 2 具有诱导细胞内 2-HG 减少,髓细胞分化阻滞失效的作用,并且在白血病母细胞和更不成熟的干细胞水平诱导粒细胞分化,可研究用于急性髓系白血病 (AML) 及其他癌症。
T62698 mIDH1-IN-1

mIDH1-IN-1 (compound 43) 是一种有效的、选择性的 mIDH1 (异柠檬酸脱氢酶 1 突变体) 抑制剂 (IC50: 961.5 nM)。mIDH1-IN-1 可以有效抑制 HT1080 细胞内 2-HG (2-hydroxyglutarate) 的产生 (EC50: 208.6±8.0 nM)。mIDH1-IN-1IDH1 突变体 U-87 细胞表现出明显的抗增殖效果(IC50: 41.8 nM)。mIDH1-IN-1 是一种抗肿瘤剂,能够用于研究 IDH1 突变实体瘤。
T78758 IHMT-IDH1-053

Isocitrate Dehydrogenase (IDH) Metabolism
IHMT-IDH1-053(compound 16)为高选择性不可逆IDH1R132H突变抑制剂,IC50值仅为4.7 nM。对IDH1wt和IDH2wt/突变体活性低。该化合物在IDH1R132H突变293T细胞中显著抑制2-羟基戊二酸(2-HG)生成,IC50为28 nM。IHMT-IDH1-053通过与IDH1R132H蛋白的Cys269残基形成共价键,结合至NADPH结合袋附近的变构袋。此外,它能够抑制携带IDH1R132突变的HT1080细胞系及原代AML细胞增殖。

化合物

Mutant IDH1 inhibitor
Cat.No: T16161
Synonym:
Target: Dehydrogenase, Isocitrate Dehydrogenase (IDH)
Mutant IDH1-IN-1
Cat.No: T2043
Synonym: IDH1-IN-1
Target: Dehydrogenase, Isocitrate Dehydrogenase (IDH)
Mutant IDH1-IN-2
Cat.No: T12128
Synonym:
Target: Isocitrate Dehydrogenase (IDH)
IDH889
Cat.No: T15551
Synonym:
Target: Dehydrogenase
IDH-305
Cat.No: T15550
Synonym:
Target: Dehydrogenase
BAY-1436032
Cat.No: TQ0042
Synonym:
Target: Dehydrogenase, Isocitrate Dehydrogenase (IDH)
Olutasidenib
Cat.No: T16384
Synonym: FT-2102
Target: Dehydrogenase, Isocitrate Dehydrogenase (IDH)
IDH1 Inhibitor 3
Cat.No: T11612
Synonym:
Target: Others
Mutant IDH1-IN-4
Cat.No: T12129
Synonym:
Target: Others
IDH1 Inhibitor 5
Cat.No: T62725
Synonym:
Target:
ML309
Cat.No: T70890
Synonym:
Target:
IDH1 Inhibitor 1
Cat.No: T11613
Synonym:
Target: Others
GSK864
Cat.No: T15442
Synonym:
Target: Others
WT IDH1 Inhibitor 2
Cat.No: T63403
Synonym:
Target:
Safusidenib
Cat.No: T63778
Synonym:
Target:
GSK321
Cat.No: T32009
Synonym: GSK 321,GSK-321
Target:
ML-309 (hydrochloride)
Cat.No: T38004
Synonym:
Target:
(S,R)-WT IDH1 Inhibitor 2
Cat.No: T63402
Synonym:
Target:
mIDH1-IN-1
Cat.No: T62698
Synonym:
Target:
IHMT-IDH1-053
Cat.No: T78758
Synonym:
Target: Isocitrate Dehydrogenase (IDH)
Cat. No. Product Name Target Signaling Pathways
T83133 Alternaphenol B2

Isocitrate Dehydrogenase (IDH) Metabolism
IDH1 Inhibitor 是一种化学化合物,其通过选择性抑制异柠檬酸脱氢酶1 (IDH1) 酶的活性来起作用。这种抑制剂对R132突变的IDH1酶特别有效,因此在某些类型的癌症治疗中具有潜在的应用价值。IDH1 Inhibitor能够阻断异常的代谢途径和纠正肿瘤细胞增殖的代谢异常。在药物研发和临床试验中,研究人员评估其对特定肿瘤生长的抑制效果及其安全性和耐受性。

天然产物

Alternaphenol B2
Cat.No: T83133
Synonym:
Target: Isocitrate Dehydrogenase (IDH)
TargetMol Loading
联系我们
400-820-0310

上海市静安区江场三路238号8楼